Background: We assessed health-related quality of life (symptoms of therapy/patient functioning/global health status), in APHINITY (pertuzumab/placebo, trastuzumab, and chemotherapy as adjuvant HER2-positive early breast cancer therapy). Methods: Patients received 1 year/18 cycles of pertuzumab/placebo with trastuzumab and chemotherapy and completed EORTC QLQ-C30 and BR23 questionnaires until 36 months post-randomisation/disease recurrence. Changes ≥10 points from baseline were considered clinically meaningful. Results: 87–97% of patients completed questionnaires. In the pertuzumab versus placebo arms, mean decrease in physical function scores (baseline → end of taxane) was −10.7 (95% CI −11.4, −10.0) versus −10.6 (−11.4, −9.9), mean decrease in global health status was −11.2 (−12.2, −10.2) versus −10.2 (−11.1, −9.2), and mean increase in diarrhoea scores (baseline → end of taxane) was +22.3 (21.0, 23.6) versus +9.2 (8.2, 10.2). Diarrhoea scores remained elevated versus baseline in the pertuzumab arm throughout HER2-targeted treatment (week 25: +13.2; end of treatment: +12.2). Role functioning was maintained in both arms. Conclusions: Improved invasive disease-free survival achieved by adding pertuzumab to trastuzumab and chemotherapy did not adversely affect the ability to conduct activities of daily living versus trastuzumab and chemotherapy alone. Patient-reported diarrhoea worsened during taxane therapy in both arms, persisting during HER2-targeted treatment in the pertuzumab arm. ClinicalTrials.gov: NCT01358877.
Patient-reported function, health-related quality of life, and symptoms in APHINITY : pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer / J. Bines, E. Clark, C. Barton, E. Restuccia, M. Procter, A. Sonnenblick, D. Fumagalli, D. Parlier, A. Arahmani, J. Baselga, G. Viale, L.L. Reaby, E. Frank, R.D. Gelber, M. Piccart, C. Jackisch, J.A. Petersen. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - 125:1(2021 Jul), pp. 38-47. [10.1038/s41416-021-01323-y]
|Titolo:||Patient-reported function, health-related quality of life, and symptoms in APHINITY : pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer|
|Settore Scientifico Disciplinare:||Settore MED/08 - Anatomia Patologica|
|Data di pubblicazione:||lug-2021|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1038/s41416-021-01323-y|
|Appare nelle tipologie:||01 - Articolo su periodico|